KalVista Pharmaceuticals, Inc. KALV 深 滬
交易中 09-20 15:31:10 美东时间
10.70
-0.300
-2.73%
華盛通- 最 高10.99
- 今 開10.98
- 成交量 18.39万股
- 最 低 10.61
- 昨 收 11.00
- 總市值 4.51亿
- 52周最高 16.88
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 7.21
- 委 比 57.20%
- 總股本 4218.83万
- 歷史最高 45.00
- 量 比 0.49
- 振 幅 3.45%
- 歷史最低 4.12
- 每 手 1
- 風險率 1.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多KalVista Pharmaceuticals Welcomes New CFO for Future Growth
KalVista Pharmaceuticals ( ($KALV) ) just unveiled an announcement. KalVista Ph...
09-11 05:00
KalVista Pharmaceuticals appoints Brian Piekos as finance chief
KalVista Pharmaceuticals (NASDAQ:KALV) said it has appointed Brian Piekos as its finance chief. Piekos has over 25 years of experience and most recently served as the CFO of Elicio Therapeutics. More ...
09-10 18:35
Cantor Fitzgerald Reiterates Overweight on KalVista Pharma
Cantor Fitzgerald analyst Charles Duncan reiterates KalVista Pharma (NASDAQ:KALV) with a Overweight.
09-10 01:16
Earnings week ahead: Adobe, Oracle, Kroger, GameStop and more
Despite a lighter earnings calendar next week, several high-profile companies are set to report their financial figures. The results could significantly influence market sentiment across key sectors s...
09-08 20:00
KalVista Pharmaceticals GAAP EPS of -$0.87 beats by $0.11
KalVista Pharmaceticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$0.87 beats by $0.11. Cash, cash equivalents and marketable securities were $174.3 million on July 31, 2024, compared to $210.4 mil...
09-05 18:34
Analysts’ Top Healthcare Picks: KalVista Pharmaceuticals (KALV), RegenXBio (RGNX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-29 19:50
KalVista Pharmaceuticals files to offer $300M mixed shelf
KalVista Pharmaceuticals (NASDAQ:KALV) files prospectus to offer mixed shelf of up to $300M. SEC Filing More on KalVista Pharmaceticals Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval...
07-12 05:08
KalVista Submits New Drug Application For FDA Review Of Sebetralstat
Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older. The FDA has a 60-day
06-18 18:32
Needham：重申KalVista Pharma(KALV.US)评级，由买入调整至买入评级, 目标价35.00美元。
Needham：重申KalVista Pharma(KALV.US)评级，由买入调整至买入评级, 目标价35.00美元。
04-11 18:11
Needham Maintains Buy on KalVista Pharma, Maintains $35 Price Target
Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.
03-12 03:52
